Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice

Imagem de Miniatura
Arquivos
art_CUNHA-JUNIOR_Cyclobenzaprine_Raises_ROS_Levels_in_Leishmania_infantum_and_2017.PDF (1.45 MB)
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
CUNHA-JUNIOR, Edezio Ferreira
ANDRADE-NETO, Valter Viana
COSTA-SILVA, Thais Alves da
ABENGOZAR, Maria A.
BARBAS, Coral
RIVAS, Luis
ALMEIDA-AMARAL, Elmo Eduardo
TEMPONE, Andre Gustavo
Citação
PLOS NEGLECTED TROPICAL DISEASES, v.11, n.1, article ID e0005281, 11p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background The leishmanicidal action of tricyclic antidepressants has been studied and evidences have pointed that their action is linked to inhibition of trypanothione reductase, a key enzyme in the redox metabolism of pathogenic trypanosomes. Cyclobenzaprine (CBP) is a tricyclic structurally related to the antidepressant amitriptyline, differing only by the presence of a double bond in the central ring. This paper describes the effect of CBP in experimental visceral leishmaniasis, its inhibitory effect in trypanothione reductase and the potential immunomodulatory activity. Methodology/Principal Findings In vitro antileishmanial activity was determined in promastigotes and in L. infantum-infected macrophages. For in vivo studies, L. infantum-infected BALB/c mice were treated with CBP by oral gavage for five days and the parasite load was estimated. Trypanothione reductase activity was assessed in the soluble fraction of promastigotes of L. infantum. For evaluation of cytokines, L. infantum-infected macrophages were co-cultured with BALB/c splenocytes and treated with CBP for 48 h. The supernatant was analyzed for IL-6, IL-10, MCP-1, IFN-gamma and TNF-alpha. CBP demonstrated an IC50 of 14.5 +/- 1.1 mu M and an IC90 of 74.5 +/- 1.2 mu M in promastigotes and an IC50 of 12.6 +/- 1.05 mu M and an IC90 of 28.7 +/- 1.3 mu M in intracellular amastigotes. CBP also reduced the parasite load in L. infantum-infected mice by 40.4 +/- 10.3% and 66.7 +/- 10.5% in spleen at 24.64 and 49.28 mg/kg, respectively and by 85.6 +/- 5.0 and 89.3 +/- 4.8% in liver at 24.64 and 49.28mg/kg, after a short-term treatment. CBP inhibited the trypanothione reductase activity with a Ki of 86 +/- 7.7 mu M and increased the ROS production in promastigotes. CBP inhibited in 53% the production of IL-6 in infected macrophages coculture. Conclusion/Significance To the best of our knowledge, this study is the first report of the in vivo antileishmanial activity of the FDA-approved drug CBP. Modulation of immune response and induction of oxidative stress in parasite seem to contribute to this efficacy.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/19149
Referências
  1. Ansari NA, 2006, CLIN IMMUNOL, V119, P339, DOI 10.1016/j.clim.2006.01.017
  2. Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
  3. BENSON TJ, 1992, BIOCHEM J, V286, P9
  4. BUFFET PA, 1995, ANTIMICROB AGENTS CH, V39, P2167
  5. Costa DL, 2013, PATHOG GLOB HEALTH, V107, P78, DOI 10.1179/2047773213Y.0000000078
  6. Costa-Silva T. A. D., 2015, J NAT PRODUCTS, V78, P653
  7. EVANS AT, 1994, BIOCHEM PHARMACOL, V48, P613, DOI 10.1016/0006-2952(94)90293-3
  8. FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489
  9. Hamilton CJ, 2003, BIOCHEM J, V369, P529, DOI 10.1042/BJ20021298
  10. Holloway GA, 2009, ANTIMICROB AGENTS CH, V53, P2824, DOI 10.1128/AAC.01568-08
  11. Jek H., 1996, AM J RESPIR CELL MOL, V14, P272, DOI [10.1165/ajrcmb.14.3.8845178, DOI 10.1165/AJRCMB.14.3.8845178]
  12. Katsuno K, 2015, NAT REV DRUG DISCOV, V14, P751, DOI 10.1038/nrd4683
  13. KUHLENCORD A, 1992, ANTIMICROB AGENTS CH, V36, P1630
  14. Kulshrestha A, 2013, PARASITOL RES, V112, P825, DOI 10.1007/s00436-012-3212-3
  15. Kumar Suresh, 2014, J Pharm Bioallied Sci, V6, P222, DOI 10.4103/0975-7406.142943
  16. Lezama-Davila CM, 2008, IMMUNOL CELL BIOL, V86, P539, DOI 10.1038/icb.2008.39
  17. Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
  18. Ribeiro GA, 2013, J ANTIMICROB CHEMOTH, V68, P789, DOI 10.1093/jac/dks498
  19. Rodrigues RF, 2012, J ANTIMICROB CHEMOTH, V67, P182, DOI 10.1093/jac/dkr409
  20. Rolao N, 2004, ACTA TROP, V90, P123, DOI 10.1016/j.actatropica.2003.09.010
  21. Thomassen MJ, 1997, AM J RESP CELL MOL, V17, P279
  22. WHO technical report series, 2010, WHO TECHN REP SER
  23. Wishah K, 2002, ANN ALLERG ASTHMA IM, V89, P78
  24. ZILBERSTEIN D, 1984, SCIENCE, V226, P977, DOI 10.1126/science.6505677
  25. ZILBERSTEIN D, 1990, BIOCHEM PHARMACOL, V39, P935, DOI 10.1016/0006-2952(90)90210-C

Coleções
Artigos e Materiais de Revistas Científicas - LIM/49
Artigos e Materiais de Revistas Científicas - IMT